Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CXCR5 | P32302 | 5/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PPIA | P62937 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308725 | 0.87 | CXCR5 (0.71) | LMNAGAACXCR5 | |
| SCHEMBL8082632 | 0.87 | LMNA (0.55) | LMNAGAACXCR5KCNK3KCNK9 | |
| SCHEMBL15825667 | 0.81 | LMNA (0.49) | LMNAGAACXCR5KCNK3KCNK9 | |
| SCHEMBL3753308 | 0.80 | GAA (0.48) | LMNAGAACXCR5KCNK3KCNK9 | |
| SCHEMBL28624943 | 0.78 | KDM4E (0.54) | LMNAGAACXCR5MEN1KMT2A | |
| SCHEMBL27775239 | 0.76 | CXCR5 (0.67) | CXCR5 | |
| SCHEMBL9830646 | 0.75 | GAA (0.75) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL16372245 | 0.74 | LMNA (0.51) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL7001833 | 0.74 | LMNA (0.68) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL464462 | 0.74 | PSMB5 (0.76) | LMNAGAACXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212334-B1 | PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-7838673-B2 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090099132-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099132-A1 | Proteasome inhibitors | PSMB5, PSMG3, PSMB1 | LMNA 2455/4885GAA 179/4885CXCR5 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.